Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | FPR1 | P21462 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxiracetam SCHEMBL15789330 | 1.00 | APEX1 (1.00) | APEX1BLMTSHRSIGMAR1RAB9A | |
| Oxiracetam SCHEMBL2596758 | 1.00 | APEX1 (1.00) | APEX1BLMTSHRSIGMAR1RAB9A | |
| Oxiracetam SCHEMBL15789157 | 0.98 | APEX1 (0.96) | APEX1BLMTSHRSIGMAR1RAB9A | |
| Oxiracetam SCHEMBL28342561 | 0.98 | APEX1 (0.96) | APEX1BLMTSHRSIGMAR1RAB9A | |
| Oxiracetam SCHEMBL28956553 | 0.98 | APEX1 (0.96) | APEX1BLMTSHRSIGMAR1RAB9A | |
| Oxiracetam SCHEMBL27586048 | 0.98 | APEX1 (0.96) | APEX1BLMTSHRSIGMAR1RAB9A | |
| Oxiracetam SCHEMBL28014647 | 0.93 | APEX1 (0.87) | APEX1BLMTSHRSIGMAR1RAB9A | |
| Oxiracetam SCHEMBL2322773 | 0.92 | APEX1 (0.84) | APEX1BLMTSHRSIGMAR1RAB9A | |
| SCHEMBL24724511 | 0.83 | APEX1 (0.71) | APEX1BLMTSHRPOLBTP53 | |
| SCHEMBL19119195 | 0.82 | APEX1 (0.70) | APEX1BLMTSHRPOLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4815 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746864-A1 | C5 KETONE COMPOSITIONS AND RELATED METHODS FOR TREATING METABOLIC DYSFUNCTION | Keto Innovations, LLC (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4744670-A1 | POLYLACTIC ACID AND USE OF COPOLYMER THEREOF IN PREPARATION OF DRUG FOR PROMOTING NERVE GROWTH AND REPAIR | Changchun Sinobiomaterials Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| WO-2026090582-A1 | COMPOSITIONS CONTAINING A NON-XANTHINE CNS STIMULANT OR NOOTROPIC AND BETA-HYDROXYBUTYRATE OR PRECURSOR FOR INCREASING NEUROLOGICAL AND PHYSIOLOGICAL PERFORMANCE | AXCESS GLOBAL SCIENCES, LLC (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4712954-A1 | C5 KETONE COMPOSITIONS AND RELATED METHODS FOR THERAPEUTIC AND PERFORMANCE SUPPLEMENTATION | Keto Innovations, LLC (US) | 2026-03-25 | — | — | EP | claimed |
| CN-120152491-A | Perovskite battery modified based on pyrrolidone derivative and preparation method thereof | 敬硕科技(河北)有限责任公司 | 2025-06-13 | — | — | CN | claimed |
| CN-120025976-A | Method for differentiating hematopoietic stem/progenitor cells into granulocytes | 苏州血霁生物科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | claimed |
| US-20250163379-A1 | METHOD FOR DIFFERENTIATING HEMATOPOIETIC STEM/PROGENITOR CELLS INTO NK CELLS | HEMACELL BIOTECHNOLOGY INC. (CN) | 2025-05-22 | — | — | US | claimed |
| CN-119950718-A | Pharmaceutical composition containing STING agonist and application thereof | 杭州星鳌生物科技有限公司 | 2025-05-09 | — | — | CN | claimed |
| CN-119633016-A | Application of gastrodia elata active ingredient in preparation of medicine for treating Alzheimer disease | 陕西中医药大学 | 2025-03-18 | — | — | CN | claimed |
| EP-0303391-A2 | Optical isomers of a spiroquinuclidine derivative | State of IsraelRepresented by the Prime Minister's OfficeThe Israel Institute for Biological Research (IL) | 1989-02-15 | — | — | EP | claimed |
| EP-0252353-A1 | 4-Benzyloxy-3-pyrrolin-2-one-1-yl-acetamide, preparation and use | LONZA AG (CH) | 1988-01-13 | — | — | EP | claimed |
| EP-0249018-A1 | 4-Alkoxy-3-pyrrolin-2-on-1-yl-acetic-acid amides, their manufacture and use | LONZA AG (CH) | 1987-12-16 | — | — | EP | claimed |
| US-4686296-A | Process for producing oxiracetam | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1987-08-11 | — | — | US | claimed |
| EP-0224256-A1 | Alkyl-4-alkoxy-2-oxo-pyrrolidin-1-yl acetate | LONZA AG (CH) | 1987-06-03 | — | — | EP | claimed |
| EP-0223328-A1 | Process for producing oxiracetam | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1987-05-27 | — | — | EP | claimed |
| EP-0216325-A2 | Process for the preparation of 4-hydroxy-2-oxo-pyrrolidin-1-yl-acetamide | LONZA AG (CH) | 1987-04-01 | — | — | EP | claimed |
| EP-0205247-A2 | Derivatives of quinuclidine | STATE OF ISRAEL, REPRESENTED BY PRIME MINISTER'S OFFICE, ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1986-12-17 | — | — | EP | claimed |
| EP-0116238-A1 | Therapeutic compositions and their use in enhancing brain function | BIOMEASURE, INC. (US) | 1984-08-22 | — | — | EP | claimed |
| US-4118396-A | PYRROLIDIN-2-ONES, CNS AGENTS | I.S.F. S.P.A. (IT) | 1978-10-03 | — | — | US | claimed |